Compare GSK plc (GSK) vs Zeta Global Holdings Corp (ZETA) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

ZETA stock trades at $21.335, down 5.3% over 24 hours, with technical indicators showing a bullish trend. The company reported strong revenue growth to $1.3 billion in 2025 but remains unprofitable with a net loss of $31.51 million. Recent strategic partnerships with Palantir, OpenAI, and Snowflake highlight Zeta's pivot toward AI infrastructure, driving positive analyst sentiment with 11 buy ratings and a $27.50 consensus price target.

ZETA presents a growth opportunity through AI adoption and enterprise expansion, but faces risks from negative cash flow and margin pressure. The stock's 29% upside to consensus target suggests potential, though profitability challenges and competitive threats require careful monitoring for sustained investor confidence.